Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Patricia Scripko

Neurology Salinas, CA Medical Doctor

NPI 1194046334 CMS profile 8736

1033 Los Palos Dr, Salinas, CA 93901

Open in the dashboard

General payments

$23,475

224 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$14,000 paid to institutions, not to them · program year 2021

Through program year 2024, Patricia Scripko of Salinas, CA is reported in the CMS Open Payments database as having received $23,475 across 224 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $14,000 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 84th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $24 1
2023 General $202 10
2022 General $303 17
2021 General $11,612 25
2020 General $9,166 48
2019 General $2,168 123

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patricia Scripko
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Patricia Scripko were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Patricia Scripko Neurology median Middle half National median
2019 $2,168 $474 $118–$2,177 $163
2020 $9,166 $367 $82–$2,309 $114
2021 $11,612 $438 $104–$2,547 $132
2022 $303 $442 $103–$2,388 $149
2023 $202 $464 $119–$2,312 $160
2024 $24 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Allergan Inc. $9,516 41 payments
  2. Biohaven Pharmaceuticals, Inc. $6,141 7 payments
  3. AbbVie, Inc. $4,952 22 payments
  4. Novartis Pharmaceuticals Corporation $482 21 payments
  5. Biogen, Inc. $180 9 payments
  6. Lilly USA, LLC $163 16 payments
  7. Amgen Inc. $150 8 payments
  8. Genzyme Corporation $137 7 payments
  9. Sunovion Pharmaceuticals Inc. $132 8 payments
  10. Mallinckrodt Enterprises LLC $126 5 payments
  11. Other $1,496 80 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $18,901 18 payments
  2. Food and Beverage $3,865 201 payments
  3. Travel and Lodging $709 5 payments
Products named General payments · program years 2019–2024
  1. UBRELVY Neuroscience $7,564 19 payments
  2. UBRELVY Neuroscience $6,608 18 payments
  3. NURTEC ODT $6,176 9 payments
  4. AIMOVIG $282 17 payments
  5. BOTOX $245 23 payments
  6. MAYZENT $167 8 payments
  7. EMGALITY $163 16 payments
  8. APTIOM $132 8 payments
  9. ACTHAR $126 5 payments
  10. ONPATTRO $124 5 payments
  11. Other $2,031 109 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

62

Median for Internal Medicine: 777

Drug cost

$3,896

Median for Internal Medicine: $73,373

Branded share of claims

19.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Memantine Hcl Generic 24 $3,397
Gabapentin Generic 14 $302
Carbidopa-Levodopa Carbidopa/Levodopa Brand 12 $125
Donepezil Hcl Generic 12 $71

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$12,790

Medicare's payments for the services billed

Medicare patients

84

Average age 75

Services billed

148

49 women, 35 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 67%
Arthritis 56%
Chronic kidney disease 50%
Heart failure 48%
Ischemic heart disease 46%
Atrial fibrillation 39%
Alzheimer's or dementia 38%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

224 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record